[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-384596-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-384596-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","novel-immunotherapeutic-approaches-to-treating-hpv-related-head-and-neck-cancer","Novel Immunotherapeutic Approaches to Treating HPV-Related Head and Neck Cancer","","Head and neck cancer remains a major global malignancy, with oropharyngeal squamous cell carcinoma (OPSCC) forming the bulk of cases in many regions. Incidence of a human papillomavirus (HPV)-driven subset of OPSCC is rising, accompanied by distinct immune microenvironment features compared with HPV-negative disease. As immunotherapy has gained approval for recurrent and metastatic settings, interest has increased in defining immunotherapeutic strategies specifically for HPV-related OPSCC. This comprehensive review summarizes immune characteristics, current challenges, and emerging opportunities for future immunotherapeutic applications.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/novel-immunotherapeutic-approaches-to-treating-hpv-related-head-and-neck-cancer/384596/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/novel-immunotherapeutic-approaches-to-treating-hpv-related-head-and-neck-cancer/384596.png","ImageObject",300,407,{"name":42,"@type":43},"Eliana","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is immunotherapy increasingly relevant for HPV-related head and neck cancer?","Question",{"text":63,"@type":64},"HPV-related OPSCC incidence is rising and has an immune microenvironment that differs from HPV-negative disease. Immunotherapy has also been approved for recurrent and metastatic head and neck cancer, increasing interest in applying it to HPV-driven disease.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role does HPV play in the development of OPSCC?",{"text":68,"@type":64},"HPV infection is identified as a major driver behind the increased incidence of OPSCC, replacing tobacco and alcohol as key contributors over recent decades.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the review cover regarding future immunotherapeutic work?",{"text":72,"@type":64},"It focuses on HPV-related OPSCC, detailing immune characteristics while highlighting current challenges and future opportunities for immunotherapeutic approaches in this virus-driven cancer.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},384596,1791100083,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":117,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":104},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","cancers   \nReview  \nNovel Immunotherapeutic Approaches to Treating HPV-Related Head and Neck Cancer  \nNabil F. Saba 1, *, Saagar Pamulapati 2, Bhamini Patel 3, Mayur Mody 4, Primož Strojan 5, Robert Takes 6, Antti A. Mäkitie 7, Oded Cohen 8, Pia Pace-Asciak 9, Jan B. Vermorken 10,11, Carol Bradford 12,  \nArlene Forastiere 13, Yong Teng 1, Andreas Wieland 12,14,15 and Alfio Ferlito 16  \nCitation: Saba, N.F.; Pamulapati, S.; Patel, B.; Mody, M.; Strojan, P.; Takes, R.; Mäkitie, A.A.; Cohen, O.;  \nPace-Asciak, P.; Vermorken, J.B.; et al. Novel Immunotherapeutic Approaches to Treating HPV-Related Head and Neck Cancer. Cancers 2023, 15, 1959. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cancers15071959  \nAcademic Editor: Wendell  \nG. Yarbrough  \nReceived: 22 February 2023  \nRevised: 9 March 2023  \nAccepted: 16 March 2023  \nPublished: 24 March 2023  \nCopyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA  \n2 Internal Medicine Program, Mercyhealth, Rockford, IL 61114, USA  \n3 Department of Internal Medicine, Emory University, Atlanta, GA 30307, USA  \n4 Hematology and Oncology Program, AdventHealth Medical Group, Calhoun, GA 30701, USA  \n5 Department of Radiation Oncology, Institute of Oncology, 1000 Ljubljana, Slovenia  \n6 Department of Otolaryngology and Head and Neck Surgery, Radboud University Medical Center, 6525 Nijmegen, The Netherlands  \n7 Department of Otorhinolaryngology—Head and Neck Surgery, Helsinki University Hospital, University of Helsinki, Research Program in Systems Oncology, FI-00014 Helsinki, Finland  \n8 Department of Otolaryngology, Ben Gurion University of the Negev, Soroka Medical Center, Be'er Sheva 84-101, Israel  \n9 Department of Otolarynology—Head and Neck Surgery, University of Toronto, Toronto, ON M5S 1A1, Canada  \n10 Department of Medical Oncology, Antwerp University Hospital, 2650 Edegem, Belgium  \n11 Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Antwerp, Belgium  \n12 Department of Otolaryngology, The Ohio State University, Columbus, OH 43212, USA  \n13 Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA  \n14 Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH 43210, USA  \n15 Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA  \n16 Coordinator of the International Head and Neck Scientific Group, 35100 Padua, Italy  \n* [Correspondence: nfsaba@emory.edu](Correspondence: nfsaba@emory.edu)  \nSimple Summary: Recent advances in immunotherapeutic approaches have spanned different tumor types including head and neck cancer. HPV-related head and Neck Cancers are virally driven tumors with notable immune characteristics and recent advances in immune targeting that desrve a closer examination. We aimed in this comprehensive review to offer a description of recent advances in immunotherapeutic applications in this disease.  \nAbstract: Head and neck cancer (HNC) is the seventh most common malignancy, with oropharyngeal squamous cell carcinoma (OPSCC) accounting for a majority of cases in the western world. While HNC accounts for only 5% of all cancers in the United States, the incidence of a subset of OPSCC caused by human papillomavirus (HPV) is increasing rapidly. The treatment for OPSCC is multifaceted, with a recently emerging focus on immunotherapeutic approaches. With the increased incidence of HPV-related OPSCC and the approval of immunotherapy in the management of rec","cbCaiuDP1RclJDXq","https://ap.wps.com/l/cbCaiuDP1RclJDXq","pdf",889190,"English","# Introduction\n## Epidemiology and risk factors\n## Rationale for immunotherapeutic focus","[{\"question\":\"Why is immunotherapy increasingly relevant for HPV-related head and neck cancer?\",\"answer\":\"HPV-related OPSCC incidence is rising and has an immune microenvironment that differs from HPV-negative disease. Immunotherapy has also been approved for recurrent and metastatic head and neck cancer, increasing interest in applying it to HPV-driven disease.\"},{\"question\":\"What role does HPV play in the development of OPSCC?\",\"answer\":\"HPV infection is identified as a major driver behind the increased incidence of OPSCC, replacing tobacco and alcohol as key contributors over recent decades.\"},{\"question\":\"What does the review cover regarding future immunotherapeutic work?\",\"answer\":\"It focuses on HPV-related OPSCC, detailing immune characteristics while highlighting current challenges and future opportunities for immunotherapeutic approaches in this virus-driven cancer. \"}]","Novel Immunotherapeutic Approaches to Treating HPV-Related Head and Neck Cancer | PDF",1790264184]